EGFR E884K

CI-VAR-00000860Explore in graph →ENST00000275493.2:c.2650G>ACIViC 1390

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Adenocarcinoma1
EGFR E884K	Erlotinib	Predictive	C	Supports Resistance	—	submitted	EID3813 In a lung adenocarcinoma patient harboring EGFR L858R (a known sensitizing mutation to EGFR tyrosine kinase inhibitor) and EGFR E884K co-mutations, EGFR E884K was reported to be refractory to erlotini… (full text at CIViC) PMID 16407879 · Choong et al., 2006 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.